secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anteris Technologies Global Corp. (AVR)
CIK:        0002011514
Form:       8-K
Filed at:   2026-02-27T23:59:59+00:00
Accession:  0001140361-26-007003
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anteris reports FY2025 revenue down 29%, net loss widens to $94M; starts PARADIGM trial
--------------------------------------------------------------------------------

- FY2025 revenue $1.9M (-29% YoY); net loss $94.1M (23% wider); cash used in ops $77.8M.
- R&D expenses $69.1M focused on DurAVR THV trial preparation; SG&A $26.1M.
- Initiated global PARADIGM pivotal trial for DurAVR THV; FDA IDE approval in Q4 2025.
- Raised $320M in early 2026 including Medtronic investment to fund trial and commercialization.
- Net tangible assets per share turned negative to ($0.01) from $1.74; all IPO proceeds fully used.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2011514/000114036126007003/0001140361-26-007003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2011514/000114036126007003/ef20066524_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-007003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer